Ignacio
Melero Bermejo
Catedrático de Universidad
Clínica Universitaria de Navarra
Pamplona, EspañaPublicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (70)
2024
-
Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer
Genes and Immunity
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities
Journal for immunotherapy of cancer, Vol. 12, Núm. 5
-
Tumor slice culture system for ex vivo immunotherapy studies
Methods in Cell Biology (Academic Press Inc.)
2023
-
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
Frontiers in Immunology, Vol. 14
2022
-
Cancer vaccines: the next immunotherapy frontier
Nature Cancer, Vol. 3, Núm. 8, pp. 911-926
-
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
ESMO Open, Vol. 7, Núm. 2
-
Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer
Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490
-
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type i conventional dendritic cells
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5
-
IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy
Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393
2020
-
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Drug Resistance Updates, Vol. 53
-
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Nature Immunology, Vol. 21, Núm. 2, pp. 120-134
2019
-
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
OncoImmunology, Vol. 8, Núm. 7
-
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
-
Immune mechanisms mediating abscopal effects in radioimmunotherapy
Pharmacology and Therapeutics, Vol. 196, pp. 195-203
2018
-
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
Nature Communications, Vol. 9, Núm. 1